Improving cancer immunotherapy by enhancing T cell signaling
Official title: Optimizing TCR-CD3 signaling for immunotherapy of cancer
Funded at New York University School of Medicine · NIH-11073098 · Data updated 2026-11-12
This study is looking at ways to make cancer treatments work better by helping your immune system's T cells recognize and fight cancer cells more effectively, while also reducing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 10, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $634,208 |
| NIH project number | 5R01CA284604-02 |
| Project ID | NIH-11073098 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that have shown limited response to current immunotherapies.
✕Less likely to help
Patients with cancers that are not amenable to T cell-based therapies may not benefit from this research.
What this research studies
This research focuses on optimizing T cell receptor (TCR)-CD3 signaling to improve the effectiveness of cancer immunotherapies. By studying how T cells recognize and respond to cancer cells, the researchers aim to enhance the immune system's ability to attack tumors while minimizing side effects. The approach involves modifying specific interactions within the TCR-CD3 complex to boost T cell responses without compromising their ability to target cancer cells accurately. This could lead to more durable and effective treatments for patients with various cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that provide longer-lasting responses in patients.
How similar studies have gone: Previous research has shown promise in enhancing T cell responses through similar signaling pathway modifications, indicating potential for success in this approach.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Krogsgaard, Michelle — New York University School of Medicine
- Study coordinator: Krogsgaard, Michelle
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.